Developer of oral, gut-targeted polymer therapeutics for the treatment of metabolic indications such as type 2 diabetes, and other chronic conditions. The company is developing a lead drug, which is orally administered, non-absorbed, gut-restricted duodenal exclusion therapy designed to replicate the metabolic effects of bariatric surgery with safety-advantages avoiding invasive complications of surgeries and procedures.
View Top Employees from Glyscend Therapeutics| Website | http://www.glyscend.com |
| Revenue | $2 million |
| Employees | 15 (10 on RocketReach) |
| Founded | 2014 |
| Address | 600 Suffolk St Suite 250, Lowell, Massachusetts 01854, US |
| Phone | (443) 961-2147 |
| Technologies |
JavaScript,
HTML,
PHP
+15 more
(view full list)
|
| Industry | Biotechnology, Business Services General, Business Services, Science and Engineering, Cosmetic Surgery, Health Care, Landscaping, Real Estate |
| Competitors | Ember Therapeutics, Metabolic Solutions Development Company, Mito BioPharm Ltd, NIVARTA INC., Viking Therapeutics, Inc. |
| SIC | SIC Code 87 Companies, SIC Code 873 Companies |
| NAICS | NAICS Code 54171 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 541714 Companies, NAICS Code 5417 Companies |
Looking for a particular Glyscend Therapeutics employee's phone or email?
Glyscend Therapeutics Questions
The Glyscend Therapeutics annual revenue was $2 million in 2024.
Ashish Nimgaonkar is the Founder, CEO and Board Member of Glyscend Therapeutics.
10 people are employed at Glyscend Therapeutics.
Glyscend Therapeutics is based in Lowell, Massachusetts.
The NAICS codes for Glyscend Therapeutics are [54171, 54, 541, 541714, 5417].
The SIC codes for Glyscend Therapeutics are [87, 873].
Top Glyscend Therapeutics Employees
-
51
-
45+
-
22
-
13
-
3
-
21
Related Companies
